This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Belmont, H M. Articles by Abramson, S. Search for Related Content PubMed PubMed Citation Articles by Belmont, H M. Articles by Abramson, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CYCLOPHOSPHAMIDE Social Bookmarking                         What's this?

New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis

Department of Rheumatology, Hospital for Joint Diseases, New York University Medical Center, Department of Medicine, Division of Rheumatology, New York University Medical Center New York, New York, USA

Marc Storch

Department of Rheumatology, Hospital for Joint Diseases, New York University Medical Center, Department of Medicine, Division of Rheumatology, New York University Medical Center New York, New York, USA

Jill Buyon

Department of Rheumatology, Hospital for Joint Diseases, New York University Medical Center, Department of Medicine, Division of Rheumatology, New York University Medical Center New York, New York, USA

Steven Abramson

Department of Rheumatology, Hospital for Joint Diseases, New York University Medical Center, Department of Medicine, Division of Rheumatology, New York University Medical Center New York, New York, USA

The medical records of patients receiving cyclophosphamide for lupus nephritis between 1987 and 1993 at the New York University/Hospital for Joint Diseases Lupus Study Group Institutions were retrospectively reviewed. We identified 45 patients (38 female, seven male) who received a mean of 9 ± 1 (range 2-23) pulses of intravenous cyclophosphamide for diffuse proliferative glomerulone phritis (n = 28), focal proliferative glomerulonephritis (n = 7), membranous nephropathy (n = 5), mesangial nephropathy with sclerosis (n = 1) or nephritis without biopsy (n = 4). Forty-two of the 45 patients received cyclophosphamide after failing steroid therapy. During a follow-up period of 52 ± 3 months, nine patients progressed to end-stage renal disease (ESRD) with three additional patients experiencing a doubling of the creatinine and two patients persistent nephrotic range proteinuria. There were no deaths directly attributable to cyclophosphamide and no patients developed hemorrhagic cystitis or malignancy. Ten of 37 women had ceased menstruating prior to cyclophosphamide therapy. Treatment-associated amenorrhea occurred in only three patients all over 27 years of age. Intermittent intravenous cyclophosphamide therapy of lupus nephritis is well tolerated and usually effective in maintaining renal function in patients unresponsive to steroids although, in our experience, 20% of patients developed ESRD and a total of 14 of 45 (30%) patients had unsatisfactory outcomes.

Key Words: systemic lupus erythematosus • cyclophosphamide • nephritis

Lupus, Vol. 4, No. 2, 104-108 (1995)
DOI: 10.1177/096120339500400205


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Mak, A. A. C. Cheak, J. Y. S. Tan, H. C. Su, R. C. M. Ho, and C. S. Lau Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression Rheumatology, August 1, 2009; 48(8): 944 - 952. [Abstract] [Full Text] [PDF]

				G. G. Illei, C. H. Yarboro, T. Kuroiwa, R. Schlimgen, H. A. Austin, J. F. Tisdale, P. Chitkara, T. Fleisher, J. H. Klippel, J. E. Balow, et al. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis Rheumatology, June 1, 2007; 46(6): 952 - 956. [Abstract] [Full Text] [PDF]

				G E Katsifis and A G Tzioufas Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide Lupus, September 1, 2004; 13(9): 673 - 678. [Abstract] [PDF]

				C C Mok, R W S Wong, and K N Lai Treatment of severe proliferative lupus nephritis: the current state Ann Rheum Dis, September 1, 2003; 62(9): 799 - 804. [Abstract] [Full Text] [PDF]

				R. John, K. Lietz, M. Schuster, Y. Naka, V. Rao, D. M. Mancini, E. A. Rose, C. R. Smith, M. C. Oz, N. M. Edwards, et al. Immunologic sensitization in recipients of left ventricular assist devices J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 578 - 591. [Abstract] [Full Text] [PDF]

				G. E. Katsifis, A. G. Tzioufas, P. G. Vlachoyiannopoulos, M. Voulgarelis, H. M. Moutsopoulos, and J. P. A. Ioannidis Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus Rheumatology, July 1, 2002; 41(7): 780 - 786. [Abstract] [Full Text] [PDF]

				G. G. Illei, H. A. Austin III, M. Crane, L. Collins, M. F. Gourley, C. H. Yarboro, E. M. Vaughan, T. Kuroiwa, C. L. Danning, A. D. Steinberg, et al. Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis Ann Intern Med, August 21, 2001; 135(4): 248 - 257. [Abstract] [Full Text] [PDF]

				K Takada, G G Illei, and D T Boumpas Cyclophosphamide for the treatment of systemic lupus erythematosus Lupus, March 1, 2001; 10(3): 154 - 161. [Abstract] [PDF]

				R. John, K. Lietz, E. Burke, J. Ankersmit, D. Mancini, N. Suciu-Foca, N. Edwards, E. Rose, M. Oz, and S. Itescu Intravenous Immunoglobulin Reduces Anti-HLA Alloreactivity and Shortens Waiting Time to Cardiac Transplantation in Highly Sensitized Left Ventricular Assist Device Recipients Circulation, November 9, 1999; 100 (2009): II-229 - II-235. [Abstract] [Full Text] [PDF]

				C A Slater, M H Liang, J W McCune, G M Christman, and M R Laufer Preserving ovarian function in patients receiving cyclophosphamide Lupus, January 1, 1999; 8(1): 3 - 10. [PDF]

				I. Martin-Suarez, D. D'Cruz, M. Mansoor, A. P. Fernandes, M. A Khamashta, and G. R V Hughes Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide Ann Rheum Dis, August 1, 1997; 56(8): 481 - 487. [Abstract] [Full Text]

				J. Gavalchin and N.A. Staines T and B cell recognition of idiotypes of anti-DNA autoantibodies Lupus, January 1, 1997; 6(3): 337 - 343. [PDF]

				W.M. Williams, N.A. Staines, S. Muller, and D.A. Isenberg Human T cell responses to autoantibody variable region peptides Lupus, December 1, 1995; 4(6): 464 - 471. [Abstract] [PDF]

				S. Itescu, E. Burke, K. Lietz, R. John, D. Mancini, R. Michler, E. Rose, M. Oz, and N. Edwards Intravenous Pulse Administration of Cyclophosphamide Is an Effective and Safe Treatment for Sensitized Cardiac Allograft Recipients Circulation, March 12, 2002; 105(10): 1214 - 1219. [Abstract] [Full Text] [PDF]